Relationships between structural and thermal properties of anhydrous and solvated crystalline forms of brodimoprim

被引:20
作者
Caira, Mino R. [1 ]
Bettinetti, Giampiero
Sorrenti, Milena
Catenacci, Laura
机构
[1] Univ Cape Town, Dept Chem, ZA-7701 Rondebosch, South Africa
[2] Univ Pavia, Dipartimento Chim Farmaceut, I-27100 Pavia, PV, Italy
基金
新加坡国家研究基金会;
关键词
brodimoprim; drug solvates; thermal analysis; X-ray diffraction;
D O I
10.1002/jps.20934
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The isolation and physicochemical characterization of four crystalline modifications of brodimoprim (5-[(4-bromo-3,5-dimethoxyphenyl)methyll-2,4-pyrimidinediamine, hereinafter BMP), a structural analog of trimethoprim (TMP), are reported. These phases include an unsolvated form of BMP, a hemihydrate (BMP-0.5H(2)O), a 1:1 solvate containing isopropanol (BM]P-C3H7OH(iso)), and a hemichloroformate (BMP-0.5CHCl(3)). Unsolvated BMP was isolated both by recrystallization from a range of common solvents as well as by thermal decomposition of the above solvates and no evidence for polymorphism was found. PXRD data indicated that the three solvates crystallize in different arrangements. Data from thermal analysis (thermogravimetry (TGA), hot stage microscopy (HSM), differential scanning calorimetry (DSQ) of the solvates containing water and iso-propanol were interpreted on the basis of their single-crystal X-ray structures which revealed that the modes of solvent inclusion in BMP-0.5H(2)O and BMP-C3H7OH(iso) may be described as 'isolated site' and 'lattice channel' type inclusions, respectively. (c) 2007 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm. Sci 96:996-1007, 2007.
引用
收藏
页码:996 / 1007
页数:12
相关论文
共 19 条
[1]   COMPARATIVE ANTIBACTERIAL SPECTRUM OF TRIMETHOPRIM AND BRODIMOPRIM [J].
AMYES, SGB .
JOURNAL OF CHEMOTHERAPY, 1993, 5 (06) :417-421
[2]  
[Anonymous], 1985, CRC HDB CHEM PHYS
[3]  
Budavari, 2001, MERCK INDEX ENCY CHE
[4]   Structural relationships, thermal properties, and physicochemical characterization of anhydrous and solvated crystalline forms of tetroxoprim [J].
Caira, MR ;
Bettinetti, G ;
Sorrenti, M .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (02) :467-481
[5]  
Conforti A, 1997, BRIT J CLIN PHARMACO, V44, P411
[6]   Efficacy and tolerability of brodimoprim at two different dosage schedules in the treatment of acute uncomplicated bacterial cystitis: Comparative study vs pefloxacin [J].
Cosmi, EV ;
Cantini, L ;
Preti, PAM ;
DiRenzo, GC ;
Abate, F ;
Balsotti, G ;
Carlomagno, G ;
Cirese, E ;
Indraccolo, R ;
LaSala, GB ;
Mearini, L ;
Minozzi, M ;
Scarpello, F .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1996, 64 (02) :207-211
[7]   In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with brodimoprim and dapsone, against Mycobacterium leprae [J].
Dhople, AM .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 1999, 12 (04) :319-323
[8]   Antimicrobial activities of dihydrofolate reductase inhibitors, used singly or in combination with dapsone, against Mycobacterium ulcerans [J].
Dhople, AM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (01) :93-96
[9]  
Farrugia L.J., 1997, J APPL CRYSTALLOGR, V30, P565
[10]   Correlation of trimethoprim and brodimoprim physicochemical and lipid membrane interaction properties with their accumulation in human neutrophils [J].
Fresta, M ;
Furneri, PM ;
Mezzasalma, E ;
Nicolosi, VM ;
Puglisi, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (12) :2865-2873